

Medicamen Biotech Limited

Investor Presentation Sep 2022



Business Review and Strategy



Medicamen Forays in Domestic Market with CVD




Domestic Oncology Product Range

Business Review and Strategy

- Received [ANVISA Brazil](#) approval for general capsules and PFS section. Now all 4 dosages forms namely Tablets, Capsule, Liquid Oral and PFS are approved with [ANVISA Brazil](#) for Bhiwadi Plant. MBL starts to file dossiers for these lines.
- The Bhiwadi plant was inspected by EU Authority in September 2022. No critical observation was reported.
- The process of filing the 100 dossiers in 10 Francophone countries is in full swing. The company has already started receiving product registrations. 15 product registration completed in Ghana.
- The finalization of distribution arrangement is in final stage.
- Filed 20 more dossiers in Ethiopia. Received 7 more product registration in Ethiopia, making total of 30 registered products which will enhance the current business profile.
- Successfully completed three validation batches of Bortozimib 3.5mg Injectable for US Market. The product is under stability for six months.

Medicamen Forays in Domestic Market with CVD

- 
- MBL is foraying into Domestic business with its subsidiary Medicamen Life Sciences Pvt Ltd. Vision of the Company is to become a most admired Pharmaceuticals organizations by offering research & data backed, affordable & quality medicines for Indian populations. To start with, the Company has entered Cardio-vascular & Diabetes (CVD) Business.
 - 33 products of CVD launched in India through its subsidiary Medicamen Life Sciences Pvt. Ltd., and more products are in pipeline.

Domestic Product Range

Diabetic

Brand Name

Product

Sitawow 50	Sitagliptin 50 mg
Sitawow 100	Sitagliptin 100 mg
Sitawow M 50/1000	Sitagliptin 50 + Metformin 1000 mg
Sitawow 50/500	Sitagliptin 50 + Metformin 500 mg
Dapica S 5/50	Sitagliptin 50 + Dapagliflozin 5 mg
Dapica S 10/100	Sitagliptin 100+ Dapagliflozin M10 g
Dapica 5	Dapagliflozin 5 mg
Dapica 10	Dapagliflozin 10 mg
Dapica M 10/500	Dapagliflozin 10 + Metformin 500
Dapica M 10/1000	Dapagliflozin 10 + Metformin 1000
Repvog .3/.5	Voglibose 0.3+ Repaglinide .5
Repvog0.3/1	Voglibose 0.3+ Repaglinide 1
Repvog0.3/2	Voglibose 0.3+ Repaglinide 2



Domestic Product Range

Hypertension

Brand Name

Product

Affotel 20	Telmisartan 20 mg
Affotel 40	Telmisartan 40 mg
Affotel 80	Telmisartan 80 mg
Affitel AM 40/5	Telmisartan 40+ Amlodipine 5mg
Affotel CT 40/6.25	Telmisartan 40 + CTD 6.25
Affotel CT40/12.5	Telmisartan 40 + CTD 12.5
Affotel Beta	Telmisartan 40+ Metoprolol 50
Affobis 1.25	Bisoprolol 1.25 mg
Affobis 2.5	Bisoprolol 2.5 mg
Affobis 5	Bisoprolol 5 mg



Domestic Product Range

Cardio-vascular

Brand Name Product

Roswow 10	Rosuvastatin 10 mg
Roswow20	Rosuvastatin 20 mg
Roswow Gold 10	Rosuvastatin 10 + ASP 75 + Clopidogrel 75
Roswow Gold 20	Rosuvastatin 20 + ASP 75 + Clopidogrel 75
Roswow CV 10	Rosuvastatin 10+ Clopidogrel 75
Roswow A 10	Rosuvastatin 10+ Asprin 75
Roswow 20 A	Rosuvastatin 20 + Asprin 75
Roswow CV 20	Rosuvastatin 20+ Clopidogrel 75
Roswow F 10	Rosuvastatin 10+ Finofibrate 160
Roswow F 20	Rosuvastatin 20+ Finofibrate 160



Domestic Oncology Product Range



Domestic Oncology Product Range





MB Medicamen Biotech Limited

Registered Office:

1506, Chiranjiv Tower, 43 Nehru Place, New Delhi- 110019

Phone: 011-47589500

E-mail: cs@medicamen.com

Website: www.medicamen.com